Lung Cancer Clinical Trial
— SESOfficial title:
Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience
| Verified date | September 2018 |
| Source | Michigan State University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Little is known about the symptom experience of persons having undergone surgery for lung
cancer. What we do know is that symptoms are common and can become severe and lasting. The
main purpose of this study is two-fold:
1. To better understand the symptom experience of persons with lung cancer prior to surgery
and for up to six weeks after returning home from the hospital.
2. To examine the role of a light physical activity program in persons who are undergoing
surgery for lung cancer for the treatment of a specific symptom.
The goals of this study include:
- Collecting information about the participant's current and prior health history,
symptoms, and health-related quality of life.
- Assessing our ability to recruit participants to the study.
- Assessing participant's level of participation.
- Evaluating the participant's satisfaction with the program.
We expect that patients after undergoing surgery for lung cancer during the recovery process
will experience multiple symptoms. We also expect to find that a light intensity physical
activity program will be feasible, acceptable, and show a positive impact on symptoms such as
cancer-related fatigue and confidence for cancer-related fatigue self-management.
Information gained from this randomized controlled trial study will be used to refine the
design of future larger-scale studies targeting symptoms such as cancer-related fatigue for
the lung cancer population.
| Status | Completed |
| Enrollment | 87 |
| Est. completion date | October 2014 |
| Est. primary completion date | October 2014 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 21 Years and older |
| Eligibility |
Inclusion Criteria: 1. Women and men at least 21 years of age with suspected NSCLC to be confirmed after surgery. 2. Planned surgical resection, not diagnostics alone, for treatment of suspected non-small cell lung cancer (NSCLC) to include such surgical approaches as open thoracotomy, video assisted thoracic surgery (VATS), and Robotic procedures. 3. Karnofsky Performance Status score of at least 70%. 4. Thoracic surgeon approval pre- and post-surgery. 5. Medically stable co-morbid conditions including cardiovascular disease such as post-myocardial infarction, stable coronary bypass graft surgery, and stable percutaneous transluminal coronary angioplasty; and mild to moderate cardiopulmonary obstructive disease. 6. Has phone access capability. 7. Able to speak and write English. 8. Able to hear and speak for phone interviews. 9. Owns a television. 10. Lives within 1.5 hours driving distance of recruitment site. Exclusion Criteria: 1. Severe impairment in seeing, hearing, and speaking. 2. Uncontrolled co-morbid conditions such as cardiac or pulmonary disease. 3. Uncontrolled hypertension. 4. Active treatment for malignancy within the past six months (other than non-melanoma skin cancer and when undergoing long-term hormonal treatment for common cancers such as breast and prostate cancer where disease is stable). 5. Presence of metastatic disease. 6. Requires portable oxygen therapy for activities of daily living. 7. Weight greater than 330 pounds (weight capacity of the Wii balance board). 8. History of photosensitive seizures. 9. Any condition or disorder that would impede safe participation as directed. 10. Plans to relocate outside the study area during the study period or unable to fully participate. 11. Diagnosed dementia. 12. Video-assisted thoracic surgery (VATS) procedure. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Michigan State University | East Lansing | Michigan |
| United States | Sparrow Hospital | East Lansing | Michigan |
| United States | West Michigan Cardiothoracic Surgeons | Grand Rapids | Michigan |
| United States | McLaren Greater Lansing, Greenlawn Campus | Lansing | Michigan |
| Lead Sponsor | Collaborator |
|---|---|
| Michigan State University | Duke University, Grand Valley State University, National Cancer Institute (NCI), Spectrum Health Hospitals |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Determine Feasibility as Measured by Rates of Recruitment. | Rates of recruitment were measured by the percentage of those eligible who enrolled. | At the beginning of the study. | |
| Primary | Feasibility as Measured by Adherence. | Adherence is the percentage of those adhering to the recommended exercise. | 6-weeks. | |
| Primary | Feasibility as Measured by Retention. | Retention is the percentage of those enrolled and completed and finished the program. | 6-weeks. | |
| Primary | Feasibility as Measured by Adverse Events. | Adverse Events is the percentage of participant's who had an adverse event. | 6-weeks. | |
| Secondary | Cancer-Related Fatigue Severity | The range of the score was 0 to 10 with 10 meaning the worst cancer-related fatigue and zero meaning no cancer-related fatigue. | At six weeks after discharge from the hospital after surgery for lung cancer. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|